GMED on NYSE
Globus Medical
Logo: globusmedical.com4
American medical device company
Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with West Pharmaceutical Services UK, MiniMed Group, Inc. or Insulet (United States), or pick any stock.
- TickerGMED on NYSE1
- Industrymedical technology1
- HeadquartersAudubon1
- Websitewww.globusmedical.com
- Legal formDelaware corporation1
- Incorporated inDE5
- Business address2560 General Armistead Avenue, Audubon, Pa 194035
- Filer categoryLarge accelerated filer5
See how the biggest companies compare on our leaderboards
Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Musculoskeletal Solutions brought in 95% of the revenue Globus Medical broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Musculoskeletal Solutions | $1.4B | $2.4B | $2.8B |
| Enabling Technologies | $120.2M | $154.0M | $141.0M |
Regions
United States brought in 81% of the revenue Globus Medical broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $1.3B | $2.0B | $2.4B |
| Outside the United States | $288.7M | $519.3M | $571.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue33¢$957.8M
- Research and development5¢$147.2M
- Selling, general and admin40¢$1.2B
- Other costs2¢$50.3M
- Income tax2¢$67.2M
- Profit18¢$537.9M
Out of $2.9B in revenue.7
Where each dollar of operating cash went, fiscal 2025
- Capital spending22¢$164.7M
- Share buybacks40¢$300.5M
- Kept or used elsewhere38¢$288.3M
Out of $753.4M of cash from operations.7
Financial statements
Every line of the income statement in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net sales | $2.9B | $2.5B | $1.6B |
| Cost of sales (exclusive of amortization of intangibles) | $957.8M | $1.0B | $548.2M |
| Research and development | $147.2M | $163.8M | $124.0M |
| Selling, general and administrative | $1.2B | $981.4M | $643.8M |
| Amortization of intangibles | $118.2M | $119.4M | $51.0M |
| Acquisition-related costs | $42.3M | $29.6M | $68.3M |
| Restructuring costs | $15.0M | $23.8M | $0 |
| Operating income/(loss) | $479.8M | $166.0M | $133.1M |
| Interest income/(expense), net | $7.1M | -$4.2M | $20.1M |
| Foreign currency transaction gain/(loss) | -$3.0M | -$43.3M | $14.3M |
| Bargain purchase gain | $117.7M | $0 | $0 |
| Other income/(expense) | $3.4M | $2.2M | -$2.1M |
| Total other income/(expense), net | $125.3M | -$45.3M | $32.3M |
| Income/(loss) before income taxes | $605.1M | $120.7M | $165.4M |
| Income tax provision/(benefit) | $67.2M | $17.7M | $42.5M |
| Net income/(loss) | $537.9M | $103.0M | $122.9M |
| Unrealized gain/(loss) on marketable securities | $448.0K | $1.5M | $13.2M |
| Foreign currency translation gain/(loss) | $21.8M | $1.8M | $1.2M |
| Total other comprehensive income/(loss), net of tax | $22.2M | $3.3M | $14.4M |
| Comprehensive income/(loss) | $560.1M | $106.3M | $137.3M |
| Basic (in USD per share) | $3.98 | $0.76 | $1.09 |
| Diluted (in USD per share) | $3.92 | $0.75 | $1.07 |
| Basic (in shares) | 135.2M shares | 135.7M shares | 113.1M shares |
| Diluted (in shares) | 137.1M shares | 137.9M shares | 114.6M shares |
Every line of the balance sheet in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $526.2M | $784.4M | |
| Short-term marketable securities | $31.1M | $105.6M | |
| Accounts receivable, net of allowances of $33,434 and $15,505, respectively | $678.9M | $557.7M | |
| Inventories | $759.3M | $659.2M | |
| Prepaid expenses and other current assets | $65.4M | $49.6M | |
| Income taxes receivable | $64.7M | $20.6M | |
| Total current assets | $2.1B | $2.2B | |
| Property and equipment, net | $564.5M | $561.9M | |
| Operating lease right of use assets | $63.8M | $49.6M | |
| Long-term marketable securities | $71.8M | $66.1M | |
| Intangible assets, net | $745.1M | $795.1M | |
| Goodwill | $1.4B | $1.4B | $1.4B |
| Other assets | $78.8M | $75.1M | |
| Deferred income taxes | $218.2M | $94.2M | |
| Total assets | $5.3B | $5.3B | |
| Accounts payable | $98.9M | $75.1M | |
| Accrued expenses | $333.6M | $260.6M | |
| Operating lease liabilities | $14.7M | $10.2M | |
| Income taxes payable | $4.2M | $10.7M | |
| Senior convertible notes | $0 | $443.4M | |
| Business acquisition liabilities | $19.5M | $33.7M | |
| Deferred revenue | $27.7M | $22.1M | |
| Total current liabilities | $498.5M | $855.9M | |
| Business acquisition liabilities, net of current portion | $82.0M | $89.5M | |
| Operating lease liabilities | $103.9M | $83.6M | |
| Deferred income taxes and other tax liabilities | $23.8M | $23.9M | |
| Other liabilities | $21.3M | $21.5M | |
| Total liabilities | $729.5M | $1.1B | |
| Additional paid-in capital | $3.2B | $3.0B | |
| Accumulated other comprehensive income/(loss) | $15.3M | -$6.9M | |
| Retained earnings | $1.4B | $1.2B | |
| Total equity | $4.6B | $4.2B | $4.0B |
| Total liabilities and equity | $5.3B | $5.3B | |
| Accounts receivable, allowances | $33.4M | $15.5M | |
| Common stock, shares authorized (in shares) | 775.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $537.9M | $103.0M | $122.9M |
| Bargain purchase gain | -$117.7M | $0 | $0 |
| Acquired in-process research and development | $0 | $12.6M | $0 |
| Depreciation and amortization | $276.8M | $253.4M | $145.5M |
| Provision for excess and obsolete inventory | $22.1M | $23.4M | $11.0M |
| Amortization of acquisition accounting fair value step-up | $26.1M | $242.1M | $79.8M |
| Stock-based compensation expense | $49.8M | $54.2M | $52.7M |
| Allowance for expected credit losses | $10.2M | $17.0M | $3.7M |
| Change in fair value of business acquisition liabilities | $13.5M | $26.5M | $17.4M |
| Change in deferred income taxes | $18.6M | -$125.9M | -$57.8M |
| (Gain)/loss on disposal of assets, net | $12.5M | $5.6M | $1.5M |
| Payment of business acquisition-related liabilities | -$17.0M | -$18.8M | -$3.0M |
| Net (gain)/loss from foreign currency adjustment | -$12.6M | $25.2M | -$13.7M |
| Accounts receivable | -$52.2M | -$78.1M | -$49.9M |
| Inventories | -$17.6M | -$29.9M | -$70.3M |
| Prepaid expenses and other assets | $11.1M | $1.1M | $1.1M |
| Accounts payable | $8.5M | $17.7M | -$14.2M |
| Accrued expenses and other liabilities | $34.2M | $5.0M | $17.1M |
| Income taxes payable/receivable | -$50.9M | -$13.4M | -$408.0K |
| Net cash provided by/(used in) operating activities | $753.4M | $520.6M | $243.5M |
| Purchases of marketable securities | -$107.5M | -$113.5M | -$100.6M |
| Maturities of marketable securities | $63.9M | $58.7M | $240.2M |
| Sales of marketable securities | $115.6M | $11.9M | $537.7M |
| Purchases of property and equipment | -$164.7M | -$115.4M | -$78.3M |
| Acquisition of businesses, net of cash acquired and purchases of intangible and other assets | -$252.5M | -$17.6M | -$296.0M |
| Acquisition of intangible assets | -$9.7M | $0 | $0 |
| Net cash provided by/(used in) investing activities | -$355.0M | -$176.1M | $303.0M |
| Payment of business acquisition-related liabilities | -$15.6M | -$45.6M | -$8.0M |
| Net proceeds from exercise of stock options | $89.8M | $110.4M | $12.4M |
| Payments related to tax withholdings for share-based compensation | -$2.9M | -$6.7M | -$10.6M |
| Repurchase of common stock | -$300.5M | -$85.8M | -$225.6M |
| Repayment of senior convertible notes | -$450.0M | $0 | $0 |
| Net cash provided by/(used in) financing activities | -$679.2M | -$27.7M | -$231.8M |
| Effect of foreign exchange rates on cash | $22.4M | $255.0K | $2.2M |
| Net increase/(decrease) in cash and cash equivalents | -$258.3M | $317.1M | $316.8M |
| Income taxes paid, net | $98.9M | $158.5M | $100.6M |
| Equity issued in conjunction with the NuVasive Merger | $0 | $0 | $2.2B |
| Accrued purchases of property and equipment | $13.5M | $9.3M | $7.1M |
| Federal | $65.4M | ||
| State | $9.3M |
Leadership
Who has led Globus Medical, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
- Chief executive officerKeith W. Pfeil Aug 27, 2025 to now16
- Chief executive officerDaniel T. Scavilla Apr 22, 2022 to Aug 27, 202517
- Chief executive officerDavid M. Demski Aug 30, 2017 to Jan 31, 202218
- Chief executive officerDavid C. Paul Aug 2, 2012 to Feb 1, 201719
- ChairDavid C. Paul Jan 24, 2018 to now20
- PresidentKeith W. Pfeil Aug 27, 2025 to now16
- PresidentDaniel T. Scavilla Apr 22, 2022 to Aug 27, 202517
- PresidentA. Brett Murphy Nov 18, 2015 to Nov 13, 201721
- PresidentDavid M. Demski Aug 2, 2012 to Jan 31, 202222
- Chief financial officerKyle Kline Aug 27, 2025 to now23
- Chief financial officerKeith W. Pfeil Aug 26, 2019 to Aug 27, 202524
- Chief financial officerDaniel T. Scavilla May 14, 2015 to Feb 11, 201925
- Chief financial officerRichard A. Baron Aug 2, 2012 to May 6, 201426
- Chief operating officerKeith W. Pfeil Jan 14, 2025 to now27
- Chief operating officerDavid M. Demski Aug 2, 2012 to Mar 2, 201522
Board members and other officers (20)
- EVP, Chief Commercial OfficerDaniel T. Scavilla Jan 24, 2020 to Jan 31, 202228
- SVP, GC, Corporate SecretaryKelly Huller Jan 24, 2020 to now29
- Chief Accounting OfficerSteven Payne Jun 11, 2013 to Feb 11, 201930
- Executive VP, US SalesA. Brett Murphy Aug 2, 2012 to Feb 6, 201831
- Vice President, OperationsDavid D. Davidar Aug 2, 2012 to Feb 4, 201632
- Board memberKeith W. Pfeil Aug 27, 2025 to now16
- Board memberDan Wolterman Sep 6, 2023 to now33
- Board memberJohn A. Deford Sep 6, 2023 to now34
- Board memberLeslie Norwalk V. Sep 6, 2023 to now35
- Board memberDaniel T. Scavilla Apr 22, 2022 to now17
- Board memberStephen T. Zarrilli May 3, 2019 to now36
- Board memberRobert Andrew Douglas Dec 17, 2019 to now37
- Board memberJames R. Tobin Sep 1, 2015 to now38
- Board memberAnn D. Rhoads Aug 2, 2012 to now39
- Board memberDan Lemaitre Aug 2, 2012 to now40
- Board memberDavid C. Paul Aug 2, 2012 to Feb 1, 201719
- Board memberDavid D. Davidar Aug 2, 2012 to now32
- Board memberDavid M. Demski Aug 2, 2012 to Jan 31, 202222
- Board memberKurt Wheeler Aug 2, 2012 to Feb 11, 201941
- General counselKelly Huller Mar 6, 2019 to Dec 19, 201942
Products and brands
- medical device
Listed on Wikidata.1
Globus develops, manufactures, and markets orthopedic implants including spine, trauma, and artificial joints.
Globus Medical makes the ExcelsiusGPS surgical robotic system for spine surgery. The robot is used for transpedicular drilling and screw placement. In November 2024, the company launched its ExcesiusHub, an advanced surgical navigation system for robotic surgical procedures.
The ADIRA XLIF Plate System aids in enhancing lateral spine surgery procedures.
From Wikipedia’s article on Globus Medical, shared under CC BY-SA 4.0.6
Acquisitions
In January 2014, Globus Medical acquired Excelsius Surgical. The Excelsius system is designed to integrate intra-operative digital imaging with a robotic surgery device to hold patients in place during surgeries "with sub-millimeter accuracy". In October of that year, the company acquired allograft tissue processor Transplant Technologies of Texas, Ltd. (TTOT). TTOT provides human tissue products, including bone allografts, biomaterials, and soft tissue products for spine, orthopedics, sports medicine, dental, and wound care markets.
In February 2015, Globus Medical acquired Branch Medical Group, a third-party manufacturer of high-precision medical devices.
In July 2016, Globus Medical acquired Alphatec Holdings, an international operations and distribution channel, for $80 million. As part of the transaction, Globus has agreed to provide Alphatec a five-year senior secured credit facility of up to $30 million.
In September 2018, Globus Medical acquired Nemaris, developers of Surgimap, a pre-operative planning software for spinal surgeons.
Read the full text
In August 2019, Globus Medical acquired privately owned StelKast, manufacturer of implants and instruments for hip and knee replacement.
In February 2023, Globus Medical acquired NuVasive in an all-stock deal valued at $3.1 billion.
From Wikipedia’s article on Globus Medical, shared under CC BY-SA 4.0.6
Controversies and legal
Controversies
In August 2007 Globus Medical settled a lawsuit initially filed by Synthes in 2004 over alleged stolen trade secrets. Former Synthes employees, who then worked for Globus, were accused of stealing 2300 electronic files containing blueprints for Synthes' products, safety-testing plans, and verbatim 510(k) filing documents. Globus paid Synthes $13.5 million and did not admit any wrongdoing.
In 2011, Synthes filed a second lawsuit against Globus Medical for infringing three patents, "asking the court to force the defendant to destroy its allegedly infringing products." Orthopedic Design & Technology Magazine reports that, "There was no finding of willful infringement in this lawsuit." A $16 million monetary damage was paid by Globus Medical in 2013.
From Wikipedia’s article on Globus Medical, shared under CC BY-SA 4.0.6
Timeline
Recent filings
- Sep 16, 20264
- Sep 15, 2026144
- Aug 19, 20264
- Aug 18, 2026144
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Jul 28, 20264
- Jun 9, 20264
- Jun 8, 20264
- Jun 5, 2026144
- Jun 4, 20268-K
- May 27, 2026SD
- May 7, 20268-K
- May 7, 202610-Q
- Apr 30, 2026SCHEDULE 13G
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.globusmedical.com1
- X (Twitter)x.com/GlobusMedical1
- WikipediaGlobus Medical
- WikidataQ18344949
- SEC EDGARCIK 1237831
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataGlobus Medical on Wikidata
- 2SEC EDGARGlobus Medical filings on SEC EDGAR
- 3WikipediaGlobus Medical on Wikipedia
- 4Company websiteGlobus Medical logo
- 5SEC EDGARGlobus Medical filings on SEC EDGAR
- 6
- 7SEC EDGARGlobus Medical 10-K for fiscal 2025
- 8SEC EDGARGlobus Medical 10-K for fiscal 2019
- 9SEC EDGARGlobus Medical 10-K for fiscal 2020
- 10SEC EDGARGlobus Medical 10-K for fiscal 2021
- 11SEC EDGARGlobus Medical 10-K for fiscal 2022
- 12SEC EDGARGlobus Medical 10-Q for fiscal 2026
- 13SEC EDGARGlobus Medical 10-Q for fiscal 2026
- 14SEC EDGARGlobus Medical 10-K for fiscal 2019
- 15SEC EDGARGlobus Medical 10-K for fiscal 2019
- 16
- 17
- 18
- 19
- 20SEC EDGARDavid C. Paul, Chair
- 21SEC EDGARA. Brett Murphy, President
- 22SEC EDGARDavid M. Demski, President
- 23SEC EDGARKyle Kline, Chief financial officer
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33SEC EDGARDan Wolterman, Board member
- 34SEC EDGARJohn A. Deford, Board member
- 35SEC EDGARLeslie Norwalk V., Board member
- 36SEC EDGARStephen T. Zarrilli, Board member
- 37SEC EDGARRobert Andrew Douglas, Board member
- 38SEC EDGARJames R. Tobin, Board member
- 39SEC EDGARAnn D. Rhoads, Board member
- 40SEC EDGARDan Lemaitre, Board member
- 41SEC EDGARKurt Wheeler, Board member
- 42SEC EDGARKelly Huller, General counsel